Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, accounting for approximately one-third of all deaths annually. Hypertension, dyslipidemia, obesity, and metabolic syndrome are among the most significant modifiable risk factors contributing to the development of coronary heart disease and other cardiovascular complications. β-blockers have occupied a central role in cardiovascular pharmacotherapy for more than five decades, particularly in the management of hypertension, ischemic heart disease, and chronic heart failure. This study aimed to evaluate the role of β-blockers in the treatment of hypertension and coronary heart disease, with special attention to their clinical efficacy, indications, and metabolic effects. Recent large-scale trials have questioned the use of traditional β-blockers, such as atenolol, as first-line therapy for primary hypertension prevention due to comparatively weaker effects on central aortic pressure and cardiovascular outcomes. Consequently, international guidelines have limited their use as initial antihypertensive agents. However, β-blockers remain strongly recommended in specific patient groups, including those with angina pectoris, previous myocardial infarction, heart failure, tachyarrhythmias, glaucoma, and pregnancy. Particular emphasis is placed on the role of sympathetic nervous system activation in hypertension and metabolic disorders. While classical β-blockers may adversely affect carbohydrate and lipid metabolism, newer vasodilatory agents such as metoprolol, carvedilol, and nebivolol demonstrate improved metabolic profiles and reduced impact on central hemodynamics. Nebivolol, in particular, shows minimal negative metabolic effects, making it preferable in patients with metabolic syndrome, obesity, and diabetes mellitus.
Pharmacotherapy For Arterial Hypertension And IHD With Beta-Blockers
DOI:
Keywords:
Abstract
References
Карпов Ю.А. Бета-блокаторы И Рациональная фармакотерапия сердечно-сосудистых заболеваний: руководство для практикующих врачей / под общ. ред. Е.И. Чазова и Ю.А. Карпова. М.: Литтерра, 2014. С. 28-36. 66
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC)//J. Hypertens. 2013. Vol. 31. №7. P. 1281-1357.
2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology H http://eurheartj.oxfordiournals.org/content/early/2013/08/28/eurhearti.eht296
McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HF A) of the ESC // Eur. Heart. J. 2012. Vol. 33. № 14. P. 1787-1847. 5. Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. 2007. Vol. 25. P. 1105— 1187.
Bradley H.A., Wiyonge C.S., Volmink V.A. et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis И J. Hypertens. 2006. Vol. 24. № 11. P. 2131-2141.
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart Disease and Stroke Statistics—2010 update. A Report From the American Heart Association. Circulation. 2010;121: el-170.
2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal (2018) 39, 3021—3104 ESC/ESH GUIDELINES doi:10.1093/eurheartj/ehy339.
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. European Heart Journal, Volume 39, Issue 9, 01 March 2018, Pages 763- 816, https://doi.org/l0.1093/eurheartj/ehx095